Companies jointly present at Medica, November 14-17, 2012, in Düsseldorf
SCIENION AG and GENOMICA S.A.Unipersonal, today announced the expansion of their strategic partnership. Both companies will offer to the life science market a jointly developed new printing plate technology platform. This new platform combines SCIENION’s non-contact arraying and surface technologies with GENOMICA’s multiplex PCR technology and microarrays detection. Both enterprises will advance in the development of new molecular applications, among which, in vitro diagnostics and personalized medicine will lead the way.
Berlin, Germany, and Madrid, Spain, November 5, 2012: Dr. Holger Eickhoff, CEO of SCIENION AG, stated: “The technologies of our companies optimally complement one another. GENOMICA has an excellent track record of successfully marketed DNA-based IVD tests and with its CLART® technology products the company is considered a benchmark in molecular diagnostics. Combining this expertise with SCIENION’s state of the art non-contact dispensing technology, our consumables such as high quality microtiter plates and our production capabilities adds up to a perfect match. We are aiming to speed up the development of better and safer in vitro diagnostics and will offer joint technology solutions for the benefit of users and last but not least also for patients.”
Dr. Rosario Cospedal, CEO of GENOMICA S.A.Unipersonal, added: “Both companies meet the highest quality standards in the development, manufacturing and commercialization of their products. GENOMICA has a highly competitive technology based on multiplex PCR and microarrays detection. The ability of this technology to detect specific targets with high sensitivity and specificity has allowed our company to expand its market and be competitive in the molecular diagnostics field. Our existing collaboration with SCIENION, a trustable and expert company in non-contact printing technology, has already proved to be a good partnership. The close and constructive cooperation between both companies is making possible to identify more subareas for joint activities and we move forward to tap the full potential”.
Based on this new printing plate technology, SCIENION and GENOMICA will jointly offer new services for customers in the microarrays life science industry. These services range from assay development to manufacturing of microarrays individually tailored to the needs and specifications of customers.
Visit us at MEDICA 2012, November 14-17, 2012, Düsseldorf, Hall 3 / Booth B60
SCIENION AG and its US subsidiary SCIENION US, Inc. provide systems and services for the contact-free printing of biological and chemical agents for diagnostics, pharmaceutics, veterinary, plant and food analytics and research. Addressing the dynamically increasing needs for miniaturization and multiplex analyses, SCIENION offers a unique technology portfolio that has been consequently expanded over one decade. SCIENION provides flexible solutions for research and development whereas solutions for production purposes are rather customized. Systems and software are characterized by its versatility, precision and robustness. The company is a renowned specialist for ultra low volume liquid handling, particularly for the handling of precious and sensitive compounds of biological or chemical origin. SCIENION’s dispensers allow for contact-free and precise drop spotting in the pico- to micro-liter range and are optimally suited for microarray based analytics – as for tests with DNA, oligonucleotides, peptides, proteins, antibodies, glycans or for dispensing cells onto various substrates. The company operates from two sites in Germany, Dortmund and Berlin, and has a subsidiary in Princeton, New Jersey, USA.
For more information, visit www.scienion.com.
GENOMICA S.A.U. develops, produces and commercializes in vitro diagnostic products as well as services for genetic identification. During the last 22 years, the company has been pioneer in molecular diagnostic tools using the multiplexing PCR technique as a basis of a sensitive, specific and robust technology. GENOMICA holds all the certifications and accreditations necessary to ensure the highest quality standards of its products and services from R&D to the market. The development of its own diagnostic platform CLART® (Clinical Array Technology) combined with a high production capacity and protocols automation has allowed the company to achieve a very successful internationalization process, being nowadays present in 40 countries all around the world.
GENOMICA has developed diagnostic tests for Human Papillomavirus, respiratory viruses, Herpes virus, Enterovirus, microorganisms causing Sepsis and Gastroenteritis. With the launch of the new kit (CLART® CMA KRAS•BRAF•PI3K) for the detection of genetic mutations involved in tumor response to therapy, GENOMICA has entered into the field of medical oncology and personalized medicine.
For more information visit www.genomica.com.
Phone +49 (0)30 – 6392 1700
Fax +49 (0)30 – 6392 1701
Pol. Industrial de Coslada, Coslada
Phone +34 91 674 89 90
Fax +34 91 674 89 91